Homepage Top Section2

FL is the most common slow-growing B-cell non-Hodgkin lymphoma form. Minjuvi is a humanised, fragment crystallisable-modified cytolytic monoclonal antibody targeting cluster of differentiation 19. The EC approval follows

Harbour BioMed will work alongside BMS to progress and expedite the programmes aimed at the discovery of the antibodies. Harbour BioMed, in exchange, is eligible to obtain payments

The expansion is targeted at individuals for whom topical corticosteroids are not sufficient or appropriate. The European regulator has accepted the application for review. The submission is based

Rett syndrome is a rare neurodevelopmental disorder that progresses through four stages. The formulation is intended to treat the condition in adult and paediatric patients aged two years

This next-generation central nervous system (CNS)-penetrant will be developed by Bleecker Bio, a newly established subsidiary of Formation. Lynk Pharmaceuticals will obtain a minority equity stake in Bleecker,

The multi-programme partnership leverages Zealand Pharma’s experience in obesity and metabolic health alongside OTR Therapeutics’ research and development (R&D) platform to address the needs of people with metabolic

Lupus nephritis classifications indicate the severity and type of kidney damage, which is central to the disease. The EC’s decision is based on outcomes from the Phase II

The licensing agreement covers Thailand, Singapore, the Philippines and Indonesia, granting Rxilient rights to market APP13007, a patented medicine for treating inflammation and pain after ocular surgery. It

With this collaboration, drug developers get access to the technology, which is designed to increase yields and reduce the time required to reach clinical trials. The ATUM’s transposase-based